Extrapyramidal Symptoms

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform

Dinesh K. Arya - One of the best experts on this subject based on the ideXlab platform.

  • Extrapyramidal Symptoms with selective serotonin reuptake inhibitors.
    British Journal of Psychiatry, 1994
    Co-Authors: Dinesh K. Arya
    Abstract:

    BACKGROUND Several case reports in the literature suggest that selective serotonin reuptake inhibitors can produce Extrapyramidal Symptoms. METHODS Computerised literature searches were used to identify reports on Extrapyramidal Symptoms and serotonin reuptake inhibitors. Subsequently, manual searches were made for articles in which there was any indication of the mechanisms responsible for these Extrapyramidal Symptoms. RESULTS Only a few reports could be identified in which serotonin reuptake inhibitors were implicated in Extrapyramidal Symptoms in some patients. CONCLUSIONS Evidence is discussed from preclinical and clinical studies suggesting the interaction between serotoninergic and dopaminergic neurotransmitter system, as a possible mechanism for production of Extrapyramidal Symptoms.

  • Extrapyramidal Symptoms with selective serotonin reuptake inhibitors.
    The British journal of psychiatry : the journal of mental science, 1994
    Co-Authors: Dinesh K. Arya
    Abstract:

    Several case reports in the literature suggest that selective serotonin reuptake inhibitors can produce Extrapyramidal Symptoms. Computerised literature searches were used to identify reports on Extrapyramidal Symptoms and serotonin reuptake inhibitors. Subsequently, manual searches were made for articles in which there was any indication of the mechanisms responsible for these Extrapyramidal Symptoms. Only a few reports could be identified in which serotonin reuptake inhibitors were implicated in Extrapyramidal Symptoms in some patients. Evidence is discussed from preclinical and clinical studies suggesting the interaction between serotoninergic and dopaminergic neurotransmitter system, as a possible mechanism for production of Extrapyramidal Symptoms.

Toshiya Inada - One of the best experts on this subject based on the ideXlab platform.

  • Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and test-retest reliability.
    Nordic journal of psychiatry, 2019
    Co-Authors: Bernhard Weidle, Ashmita Chaulagain, Kenneth Stensen, Branko Aleksic, Norbert Skokauskas, Toshiya Inada
    Abstract:

    Background: The Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) is a multidimensional rating scale designed for the fast, easy and reliable assessment of Extrapyramidal Symptoms (EPSs) induced ...

  • drug induced Extrapyramidal Symptoms scale diepss serbian language version inter rater and test retest reliability
    Scientific Reports, 2017
    Co-Authors: Ami Peljto, Branko Aleksic, Ljubica Zamurovic, Milica Pejovic Milovancevic, Dusica Lecic Tosevski, Toshiya Inada
    Abstract:

    Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) is developed in the era of second-generation antipsychotics and is suitable for evaluation of the low incidence of Extrapyramidal Symptoms occurring in the treatment of atypical antipsychotics, as well as the relationship between personal and social functioning. The study was carried out at the Institute of Mental Health in Serbia in 2015 Study used the 127 DIEPSS video clips material, recorded from 1987 till 2015. Four raters performed the assessment simultaneously, individually rating one assigned item immediately after seeing the video clip. For the purpose of evaluating test-retest reliability the second assessment of the same material was performed nine months after the first assessment. Inter-rater reliability was high for each individual item, with ICCs ranging from 0.769 to 0.949. The inter-rater reliability was highest for akathisia item and lowest for dyskinesia. The test-retest reliability was high for each individual item, with ICC ranging from 0.713 to 0.935. The test-retest reliability was highest for bradykinesia item and lowest for dystonia. The Serbian version of DIEPSS has high level of inter-rater and test-retest reliability. High values of concordance rates (ICC > 0.7) for each evaluated individual item suggest that items of DIEPSS are well defined.

  • Current topics in neuroleptic-induced Extrapyramidal Symptoms in Japan.
    The Keio journal of medicine, 1996
    Co-Authors: Toshiya Inada, Gohei Yagi
    Abstract:

    This article reviews current topics in neuroleptic-induced Extrapyramidal Symptoms in Japan, focusing especially on the clinical features of akathisia and dystonia. Akathisia is a common side effect associated with antipsychotic drugs. It is most commonly characterized by subjective inner restlessness and objective motor signs, especially in the lower extremities. The mechanisms underlying akathisia remain unclear and controversial; however, an increase in the activity of β-adrenergic systems relative to dopaminergic systems has been hypothesized, based on clinical therapeutic observations that β-blocking agents are effective in this condition. A Japanese version of the Barnes Akathisia Scale has recently been established and uses a standardized videotape method for its precise evaluation. Various acute and chronic manifestations of neuroleptic-induced dystonia have been reported in Japan, including blepharospasm, difficulty in opening the eye lids, torticollis, retrocollis, oculogyric crisis, and Pisa syndrome. This review also introduces several other topics related to drug-induced Extrapyramidal Symptoms in Japan. These include; 1) the Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), which has recently been established, 2) studies on the discontinuation of anticholinergic drugs, and 3) a summary of Extrapyramidal Symptoms induced by drugs other than neuroleptics.

José Antonio Molina - One of the best experts on this subject based on the ideXlab platform.

  • Extrapyramidal Symptoms Associated with Selective Serotonin Reuptake Inhibitors
    CNS Drugs, 2000
    Co-Authors: Félix Javier Jiménez-jiménez, José Antonio Molina
    Abstract:

    In recent years there has been an increasing number of reports of the development or aggravation of parkinsonism and the development of other movement disorders (‘Extrapyramidal Symptoms’) associated with exposure to the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) fluoxetine, paroxetine, sertraline, fluvoxamine and citalopram. The exact prevalence of these complications is unknown since available information comes from literature reviews of case reports or data from the manufacturers or from movement disorders units and is therefore subject to reference bias. In addition, many of the patients had previously received or were concurrently being treated with other drugs, mainly antipsychotics. Reported movement disorders include parkinsonism, akathisia, tremor, dystonia, tardive dyskinesia, myoclonus, tics and chorea; parkinsonism and akathisia were the most frequent. Pathophysiological mechanisms are not well established, but the most accepted hypotheses suggest a relationship with interactions between serotonergic and dopaminergic neurotransmitter systems. Anatomical, physiological and pharmacological relationships between these two systems are reviewed in this article. The management of SSRI-induced movement disorders includes avoidance of SSRI use, dose reduction or discontinuation of the offending drug and the same measures that are used for treating antipsychotic-induced movement disorders.

Amalia Lafuente - One of the best experts on this subject based on the ideXlab platform.

Deborah V Kelly - One of the best experts on this subject based on the ideXlab platform.

  • Extrapyramidal Symptoms with ritonavir indinavir plus risperidone
    Annals of Pharmacotherapy, 2002
    Co-Authors: Deborah V Kelly, Lizanne C Beique, Ian M Bowmer
    Abstract:

    OBJECTIVE:To report a case of suspected Extrapyramidal Symptoms (EPS) in a patient initiated on ritonavir and indinavir while taking risperidone for a tic disorder.CASE SUMMARY:A 35-year-old white man with AIDS received risperidone 2 mg twice daily for treatment of a Tourette's-like tic disorder. Ritonavir and indinavir were initiated, and 1 week later, he experienced significantly impaired swallowing, speaking, and breathing, and worsening of his existing tremors. Ritonavir and indinavir were discontinued. On the same day, the patient increased the risperidone dosage to 3 mg twice daily. Symptoms continued to worsen over the next 3 days. All investigations and laboratory parameters were unremarkable, and vital signs were stable. Risperidone was discontinued and clonazepam initiated. Three days later, the patient's Symptoms were significantly improved.DISCUSSION:The Symptoms described herein are consistent with neuroleptic-induced acute dystonia and potentially neuroleptic-induced parkinsonism. We believe...

  • Extrapyramidal Symptoms with Ritonavir/Indinavir Plus Risperidone
    The Annals of pharmacotherapy, 2002
    Co-Authors: Deborah V Kelly, Lizanne C Beique, M Ian Bowmer
    Abstract:

    OBJECTIVE:To report a case of suspected Extrapyramidal Symptoms (EPS) in a patient initiated on ritonavir and indinavir while taking risperidone for a tic disorder.CASE SUMMARY:A 35-year-old white man with AIDS received risperidone 2 mg twice daily for treatment of a Tourette's-like tic disorder. Ritonavir and indinavir were initiated, and 1 week later, he experienced significantly impaired swallowing, speaking, and breathing, and worsening of his existing tremors. Ritonavir and indinavir were discontinued. On the same day, the patient increased the risperidone dosage to 3 mg twice daily. Symptoms continued to worsen over the next 3 days. All investigations and laboratory parameters were unremarkable, and vital signs were stable. Risperidone was discontinued and clonazepam initiated. Three days later, the patient's Symptoms were significantly improved.DISCUSSION:The Symptoms described herein are consistent with neuroleptic-induced acute dystonia and potentially neuroleptic-induced parkinsonism. We believe...

Related terms

Extrapyramidal Symptoms - 15 days free trial to Access Experts & Abstracts